Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.

You may also be interested in...



J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration

Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.

J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration

Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.

Eisai Licenses U.S. Rights To Fragmin From Pfizer

Agreement to license the dalteparin sodium anti-coagulant is aimed at strengthening Eisai’s position in the U.S. critical care market.

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel